69 related articles for article (PubMed ID: 17011185)
1. Mutational analysis of beta-catenin and the RAS-RAF signalling pathway in early flat-type colorectal tumours.
Mikami M; Nosho K; Yamamoto H; Takahashi T; Maehata T; Taniguchi H; Adachi Y; Imamura A; Fujita M; Hosokawa M; Itoh F; Imai K; Shinomura Y
Eur J Cancer; 2006 Nov; 42(17):3065-72. PubMed ID: 17011185
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers.
Nosho K; Yamamoto H; Takahashi T; Mikami M; Taniguchi H; Miyamoto N; Adachi Y; Arimura Y; Itoh F; Imai K; Shinomura Y
Carcinogenesis; 2007 Jun; 28(6):1364-70. PubMed ID: 17183069
[TBL] [Abstract][Full Text] [Related]
3. Frequent involvement of ras-signalling pathways in both polypoid-type and flat-type early-stage colorectal cancers.
Noda H; Kato Y; Yoshikawa H; Arai M; Togashi K; Nagai H; Konishi F; Miki Y
J Exp Clin Cancer Res; 2006 Jun; 25(2):235-42. PubMed ID: 16918136
[TBL] [Abstract][Full Text] [Related]
4. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
5. Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas.
Bläker H; Helmchen B; Bönisch A; Aulmann S; Penzel R; Otto HF; Rieker RJ
Scand J Gastroenterol; 2004 Aug; 39(8):748-53. PubMed ID: 15513360
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
[TBL] [Abstract][Full Text] [Related]
7. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation.
Nagasaka T; Sasamoto H; Notohara K; Cullings HM; Takeda M; Kimura K; Kambara T; MacPhee DG; Young J; Leggett BA; Jass JR; Tanaka N; Matsubara N
J Clin Oncol; 2004 Nov; 22(22):4584-94. PubMed ID: 15542810
[TBL] [Abstract][Full Text] [Related]
8. Sessile serrated adenoma with early neoplastic progression: a clinicopathologic and molecular study.
Fujita K; Yamamoto H; Matsumoto T; Hirahashi M; Gushima M; Kishimoto J; Nishiyama K; Taguchi T; Yao T; Oda Y
Am J Surg Pathol; 2011 Feb; 35(2):295-304. PubMed ID: 21263251
[TBL] [Abstract][Full Text] [Related]
9. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.
Oliveira C; Velho S; Domingo E; Preto A; Hofstra RM; Hamelin R; Yamamoto H; Seruca R; Schwartz S
Oncogene; 2005 Nov; 24(51):7630-4. PubMed ID: 16007118
[TBL] [Abstract][Full Text] [Related]
10. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
[TBL] [Abstract][Full Text] [Related]
11. Flat-type colorectal advanced adenomas (laterally spreading tumors) have different genetic and epigenetic alterations from protruded-type advanced adenomas.
Takahashi T; Nosho K; Yamamoto H; Mikami M; Taniguchi H; Miyamoto N; Adachi Y; Itoh F; Imai K; Shinomura Y
Mod Pathol; 2007 Jan; 20(1):139-47. PubMed ID: 17143260
[TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression.
Calistri D; Rengucci C; Seymour I; Lattuneddu A; Polifemo AM; Monti F; Saragoni L; Amadori D
J Cell Physiol; 2005 Aug; 204(2):484-8. PubMed ID: 15702478
[TBL] [Abstract][Full Text] [Related]
13. Macroscopic morphologic subtypes of laterally spreading colorectal tumors showing distinct molecular alterations.
Sugimoto T; Ohta M; Ikenoue T; Yamada A; Tada M; Fujishiro M; Ogura K; Yamaji Y; Okamoto M; Kanai F; Kawabe T; Omata M
Int J Cancer; 2010 Oct; 127(7):1562-9. PubMed ID: 20091866
[TBL] [Abstract][Full Text] [Related]
14. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
15. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.
Artale S; Sartore-Bianchi A; Veronese SM; Gambi V; Sarnataro CS; Gambacorta M; Lauricella C; Siena S
J Clin Oncol; 2008 Sep; 26(25):4217-9. PubMed ID: 18757341
[No Abstract] [Full Text] [Related]
16. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
[TBL] [Abstract][Full Text] [Related]
17. Large-scale N-terminal deletions but not point mutations stabilize beta-catenin in small bowel carcinomas, suggesting divergent molecular pathways of small and large intestinal carcinogenesis.
Breuhahn K; Singh S; Schirmacher P; Bläker H
J Pathol; 2008 Jul; 215(3):300-7. PubMed ID: 18491352
[TBL] [Abstract][Full Text] [Related]
18. Mutant K-ras promotes carcinogen-induced murine colorectal tumourigenesis, but does not alter tumour chromosome stability.
Luo F; Poulogiannis G; Ye H; Hamoudi R; Zhang W; Dong G; Arends MJ
J Pathol; 2011 Feb; 223(3):390-9. PubMed ID: 21171084
[TBL] [Abstract][Full Text] [Related]
19. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.
Oliveira C; Velho S; Moutinho C; Ferreira A; Preto A; Domingo E; Capelinha AF; Duval A; Hamelin R; Machado JC; Schwartz S; Carneiro F; Seruca R
Oncogene; 2007 Jan; 26(1):158-63. PubMed ID: 16953233
[TBL] [Abstract][Full Text] [Related]
20. Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome.
Johnson V; Volikos E; Halford SE; Eftekhar Sadat ET; Popat S; Talbot I; Truninger K; Martin J; Jass J; Houlston R; Atkin W; Tomlinson IP; Silver AR
Gut; 2005 Feb; 54(2):264-7. PubMed ID: 15647192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
